Havemeyer Place LP Makes New $2.18 Million Investment in Labcorp Holdings Inc. $LH

Posted by Geri Gentry on Jun 7th, 2026

Havemeyer Place LP purchased a new position in shares of Labcorp Holdings Inc. (NYSE:LH – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 8,678 shares of the medical research company’s stock, valued at approximately $2,177,000.

Other institutional investors also recently modified their holdings of the company. JPL Wealth Management LLC acquired a new stake in shares of Labcorp during the 3rd quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Labcorp during the 4th quarter worth approximately $26,000. Eagle Bay Advisors LLC acquired a new stake in shares of Labcorp during the 4th quarter worth approximately $29,000. Hantz Financial Services Inc. grew its position in shares of Labcorp by 48.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock worth $35,000 after buying an additional 40 shares during the period. Finally, Headlands Technologies LLC grew its position in shares of Labcorp by 300.0% during the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after buying an additional 96 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Stock Performance

Shares of LH stock opened at $265.80 on Friday. The company’s fifty day simple moving average is $262.75 and its 200-day simple moving average is $265.62. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The firm has a market cap of $21.80 billion, a PE ratio of 23.54, a P/E/G ratio of 1.86 and a beta of 0.90. Labcorp Holdings Inc. has a 12 month low of $241.81 and a 12 month high of $293.72.

Labcorp (NYSE:LH – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Equities research analysts expect that Labcorp Holdings Inc. will post 18 EPS for the current fiscal year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp’s payout ratio is currently 25.51%.

Insider Activity at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,903 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $254.50, for a total value of $1,502,313.50. Following the transaction, the chief executive officer directly owned 107,234 shares in the company, valued at $27,291,053. The trade was a 5.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.84% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Piper Sandler boosted their price objective on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. boosted their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Robert W. Baird set a $334.00 price objective on shares of Labcorp in a report on Friday, May 1st. Finally, Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $308.00.

Read Our Latest Stock Report on LH

Labcorp Company Profile

(Free Report)

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.